Related Experiment Video
Updated: Nov 23, 2025
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.6K
[PROGNOSIS ASSESSMENT OF THE COMBINED COURSE OF STABLE CORONARY HEART DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS IN
I Vakalyuk1, N Virstyuk1, I Vakaliuk1
1Ivano-Frankivsk National Medical University, Ukraine.
Georgian Medical News
|January 4, 2021
Summary
Patients with stable coronary heart disease and non-alcoholic steatohepatitis (NASH) show increased fibrosis progression. The combination of NASH and a high FIB-4 index indicates a poor two-year prognosis after revascularization.
Area of Science:
- Cardiology
- Hepatology
- Fibrosis Research
Background:
- Stable coronary heart disease (CHD) and non-alcoholic steatohepatitis (NASH) are prevalent conditions.
- The combined impact of CHD and NASH on cardiovascular events and prognosis requires further investigation.
Purpose of the Study:
- To evaluate the likelihood of major cardiovascular events in patients with stable CHD and NASH post-revascularization.
- To assess the role of fibrogenesis indicators in predicting outcomes for these patients.
Main Methods:
- Observational study of 164 patients with stable CHD, divided into groups with (n=54) and without (n=110) NASH.
- Utilized clinical examination, ECG, coronary angiography, echocardiography, liver function tests, and fibrosis markers.
- Long-term prognosis assessed using Kaplan-Meier analysis.
Main Results:
- Patients with coexisting CHD and NASH exhibited significant fibrosis progression, indicated by elevated fibrogenesis markers.
- NASH presence exacerbates CHD, leading to a negative two-year prognosis.
- Prognosis after coronary artery stenting is significantly worse with coexisting NASH, particularly when the FIB-4 index is ≥2.0.
Conclusions:
- Non-alcoholic steatohepatitis negatively impacts the prognosis of patients with stable coronary heart disease.
- Fibrosis progression markers, especially in conjunction with NASH and a high FIB-4 index, are crucial for predicting adverse cardiovascular outcomes.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
126
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
126
01:30Acute Coronary Syndrome III: Diagnostic Studies
95
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
95
01:28Acute Coronary Syndrome IV: Interprofessional Care
96
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
96
01:29Chronic Pancreatitis II: Collaborative Care
180
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
180
01:22Myocarditis IV: Nursing Management
107
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
107
01:26Atherosclerosis III: Management
136
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
136